Please login to the form below
Donanemab
This page shows the latest Donanemab news and features for those working in and with pharma, biotech and healthcare.
Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval
This meant many patients were able to stop treatment after six months, resulting in fewer than 100 patients receiving 12 months of donanemab. ... The company’s application was based on results from a phase 2 trial in which donanemab demonstrated
Latest news
-
Eli Lilly shares adjusted financial guidance for 2023
Reuters noted that analysts have observed Lilly’s increased spending on R&D “ahead of presenting data for its keenly watched donanemab drug for Alzheimer's disease as well as its
-
Lilly’s donanemab shows promise in early symptomatic Alzheimer's comparator study
In a key secondary outcome, donanemab reduced brain amyloid levels versus baseline by 65.2% compared with 17.0% for Aduhelm at six months. ... Additionally, an exploratory outcome showed donanemab, but not Aduhelm, significantly reduced plasma P-tau217
-
Eli Lilly focuses on 2022 launches as revenues climb by 18%
The first is that Lilly has started a rolling submission to the US Food and Drug Administration (FDA) for accelerated approval of donanemab in early Alzheimer's disease. ... through 2030, bolstered by multiple pipeline readouts of its
-
Rolling submission granted for Biogen/Eisai's next Alzheimer’s antibody
In June, Eli Lilly received breakthrough therapy designation for its Alzheimer’s therapy, donanemab.
-
Lilly restructures in preparation for Alzheimer’s drug launch
This includes the company’s potential drug for Alzheimer’s disease, donanemab, which received breakthrough therapy designation in June based on its phase 2 data. ... Importantly, this data links the mechanism of action of donanemab, plaque clearance,
More from news
Approximately 7 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Alzheimer’s: the search for a cure
Recently published study results for aducanumab and donanemab, both antibodies against amyloid, showed effects that indicated some improvement in cognition and daily function in patients with early Alzheimer’s. ... In the aforementioned aducanumab and
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- AstraZeneca joins UK pilot evaluating AI-based lung cancer diagnosis system
- Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval
- EU to revise pharmaceuticals law amid antibiotic shortages
- Medical Affairs: centre-stage in scientific engagement strategies
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Tidepool’s automated insulin dosing app for type 1 diabetes gets FDA approval
- UK to introduce new regulatory framework for point of care manufacturing
- Navigating the patient experience to improve retention of clinical trial participants
- Europe’s cancer community publishes new report on transforming patient care
- Alzheimer’s Research UK welcomes government’s pledge to tackle dementia crisis
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- EU to revise pharmaceuticals law amid antibiotic shortages
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Why everyone in pharma is bending over backwards to be agile
PMHub
IPG Health Medical Communications
We are the world's most celebrated and awarded Medical Communications agencies. We are 800 experts obsessed with combining science, creativity...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
